Fig. 8

PWAR6 is a potential therapeutic target for CRC. A Graphical diagram of vein tail injection of in vivo optimized PWAR6 inhibitor and FAPI gavage in C57BL/c mice. B–E Representative images of xenograft tumors (B, C) and liver metastasis (D, E) from each mouse group are shown. Mice with xenograft tumors were treated with either an antisense oligonucleotide control (ASO-Ctrl), an in vivo optimized PWAR6 inhibitor (ASO-PWAR6), or a combination of ASO-PWAR6 and FAPI administered via gavage. (n = 5 mice per group). F, G Representative images of NK1.1 and α-SMA IHC staining of xenograft tumors and liver metastasis in each group. Scale bars = 100μm. (n = 3, one of three biological replicates). H, I Representative images of pan-CK, α-SMA, CD3 and CD56 staining in tumor tissues from CRC cancer in FUSCC Cohort2. Scale bars = 50μm. (n = 3, one of three biological replicates). Data are shown as mean ± s.e.m. For B-E, data were analyzed by one-way ANOVA. P values. *P < 0.05, **P < 0.01, ***P < 0.001